Retreatment with epidermal growth factor receptor inhibitor after initial failure in advanced non-small cell lung cancer

Chinese Journal of Lung Cancer

Volumn 14, Issue 3, 2011, Pages 261-265

  An, Tongtong ^a   Huang, Zhen ^b   Wang, Yuyan ^a   Wang, Zhijie ^a   Bai, Hua ^a   Wang, Jie ^a  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^b Beijing Jishuitan Hospital   (China)

Author keywords

Erlotinib; Fctor receptor tyrosine kinase inhibitor; Gefitinib; Lung neoplasms

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR;

ADVANCED CANCER; ARTICLE; CANCER CONTROL; CANCER SURVIVAL; EXON; GENE MUTATION; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MONOTHERAPY; PROGRESSION FREE SURVIVAL; RETREATMENT; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETREATMENT; RETROSPECTIVE STUDIES; TREATMENT FAILURE;

EID: 79953172959     PISSN: 10093419     EISSN: 19996187     Source Type: Journal    
DOI: 10.3779/j.issn.1009-3419.2011.03.22     Document Type: Article

References (16)

1. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet, 2005, 366(9496): 1527-1537.
2. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med, 2005, 353(2): 123-132.
3. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol, 2010, 11(2): 121-128.
4. Kim ES, Hirsh V, Mok T, et al. fitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet, 2008, 372(9652): 1809-1818.
5. Makoto M, Akira I, Kunihiko K, et al. Gefitinib or chemotherapy for nonsmall- cell lung cancer with mutated EGFR. N Engl J Med, 2010, 362(25): 2380-2388.
6. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med, 2009, 361(10): 947-957.
7. Zhou C, Wu YL, Chen G, et al. Efficacy results from the randomised phase III OPTIMAL (CTONG 0802) study comparing first-line erlotinib versus carboplatin (CBDCA) plus gemcitabine (GEM), in Chinese advanced nonsmall- cell lung cancer (NSCLC) patients (pts) with EGFR activating mutations. 35th European Society for Medical Oncology Congress; 2010 Oct 8-12; Milan, Italy.
8. Roberts PJ, Stinchcombe TE, Der CJ, et al. Personalized medicine in nonsmall- cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy? J Clin Oncol, 2010, 28(31): 4769-4777.
9. Bai H, Mao L, Wang HS, et al. Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer. J Clin Oncol, 2009, 27(16): 2653-2659.
10. Maruyama R, Wataya H, Seto T, et al. Treatment after the failure of gefitinib in patients with advanced or recurrent non-small cell lung cancer. Anticancer Research, 2009, 29(10): 4217-4221.
11. Wu JY, Shih JY, Yang CH, et al. Second-line treatments after first-line gefitinib therapy in advanced non-small cell lung cancer. Int J Cancer, 2010, 126(1): 247-255.
12. Watanabe S, Tanaka J, Ota T, et al. Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis. BMC Cancer, 2011, 11: 1.
13. Kaira K, Naito T, Takahashi T, et al. Pooled analysis of the reports of erlotinib after failure of gefitinib for non-small cell lung cancer. Lung Cancer, 2010, 68(1): 99-104.
14. Lynch TJ, Bell DW, Sordella R, et al. Activating Mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N Engl J Med, 2004, 350(21): 2129-2139.
15. Zhu CQ, da Cunha Santos G, Ding K, et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol, 2008, 26(26): 4268-4275.
16. Carey KD, Garton AJ, Romero MS, et al. Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. Cancer Res, 2006, 66(16): 8163-8171.